Pfizer vs. Novo Nordisk: The Power Struggle for the Future of Weight Loss Injection

In the global race for the most lucrative medication category of the present, the competition between Pfizer (NYSE: PFE) and Novo Nordisk (OMXCOP: NOVO_B) is intensifying. As reported by the Wall Street Journal, the dispute escalated when Novo Nordisk made a surprise bid of $9 billion for the biotech company Metsera - a takeover target that Pfizer had already secured contractually for up to $7.3 billion. Novo Nordisk, known for its blockbusters like Ozempic and Wegovy, is trying to outmaneuver the US pharmaceutical giant while also closing the...